Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IIA, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose, safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity trial of AAB-001 [bapineuzumab] in patients with mild to moderate AD [Alzheimer's disease].

X
Trial Profile

A phase IIA, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose, safety, tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity trial of AAB-001 [bapineuzumab] in patients with mild to moderate AD [Alzheimer's disease].

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bapineuzumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors JANSSEN Alzheimer Immunotherapy
  • Most Recent Events

    • 15 Jul 2010 Results from a substudy measuring cerebrospinal fluid (CSF) tau proteins presented at the International Conference on Alzheimer's Disease and Related Disorders in July 2010 (Abstract O3-05-01), according to a Intellect Neurosciences media release.
    • 10 Jul 2010 Substudy results and a pooled analysis of substudies presented at the 2010 International Conference on Alzheimer's Disease and Related Disorders.
    • 15 Dec 2009 Efficacy outcomes were reported in Neurology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top